Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
61. De Veber G, Monagle P, Chan A, et al. Prothrombotic disorders in infants and shildren with cerebral thromboembolism Arch Neurol, 1998; 55: 1539—1543.
62. McColl MD, Chalmers EA, Thomas A, et al. Factor V Leiden, prothrombin 20210G, and the MTHFR C677T mutations in childhood stroke. Thromb Haemost 1999; 81: 690—694.
63. Andre E, Siguret V, Alhenc-Gelas M, Saint-Jean O, Gausserm P. Venous thrombosis in older people: prevalence of the factor V gene mutation Q506. J Am Geriart Soc 1998; 46: 2069—2073.
64. Hamsten. A, Norberg R, Bjorkholm M, de Fairc. U, Holm. G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1:113—116.
65. Morton KE, Gavaghan TP, Krilis SA, Daggard GE, Baron DW Hiskie JB, Chestcrman. CN. Coronary artery bypass graft failure — an autoimmune phenomenon? Lancet 1986:11: 1353—1357.
66. De Caterina R, DArcanio A, Mazone A, Gazzeiii P, Bernini W, Neri R, Bombardieri S, Prevalence of anlicardiolipin antibodies in coronary artery disease. Am J Cardiol 1990: 65:922— 924.
67. Conellaro M, Cofrancesco E, Boscheni C. Cardiolipin antibodies in survivors of myocardial infarction. Lancet 1993; 342: 192.
68. Sletnes KE, Smith P, Abdelnoor M, Amesen H, Wislof. F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 1992: 339: 451—453.
69. Yilmaz E, Adalet K, Yilmaz G, Badur S, Erzengin F, Koylan. N, et al. Importance of serum anlicardiolipin antibody levels in coronary heart disease. Clin Cardiol 1994; 17(3): 117—121.
70. Raghavan C, Dilchncld J, Taylor RJ, Haeney M.R, Bames P. C. Influence of anlicardi-olipin antibodies on immediate patient outcome after myocardial infarction. J Clin Pathalol 1993; 46(12): 1; 113—1115.
SHS-OOO4.qxd 21.11.2006 16:56 Page 35
5
.ГЛАВА 1. Эпидемиология антифосфолипидного синдрома
71. Klemp P, Cooper RC, Strauss FJ, Jordaan ER, Przybojewski JZ, Neri N. Anticardiolipin antibodies in ischemic heart disease. Clin Exp Immunol 1988; 74: 254—257.
72. Eber B, Schumacher M, Auer-Grumbach P, et.al. Increased IgM anticardiolipin antibodies in patients with restenosis after percutaneous trans-luminal coronary angioplasty. Amer J Cardiol 1992; 69: 1255—1258.
73. Насонов ЕЛ, Ноева ЕА, Ковалев ВЮ, Драгнев АА, Лопаева ОВ, Руда МЯ. Антитела к кардиолипину у больных инфарктом миокарда и нестабильной стенокардией. Кардиология, 1992; 5:32—34.
74. Bili A, Moss AJ, Francis CW et al. Anticardiolipin antibodies and reccurent coronary events. A prospecive study of 1150 patients. Circulation 2000; 102: 1258—1263.
75. Farsi, A, Domeneghetti, MP, Fedi, S, et al. High prevalence of anti-beta2 glycoprotein I antibodies in patients with ischemic heart disease. Autoimmunity 1999; 30: 93.
76. Puisieux F, de Groote P, Masy E, et al. Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease. Am J Med 2000; 109: 635.
77. Zuckerman E, Toubi E, Shiran A, et al. Anticardiolipin antibodies and acute myocardial infarction in non-SLE patients: A controlled prospective study. Am J Med 1996; 100: 381.
78. Aoki K, Hayashi Y, Hirao Y, Yagami Y. Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss. Am JReprod Immunol 1993; 29: 82—87.
79. Lockshin MD. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985; 313: 152—156.
80. Silver RM. Anticardiolipin antibodies: clinical consequences of low titer. Obstet Gynecol 1996; 87: 494—500.
81. Kutteh WH. Antiphospholipid antibodies and reproduction. J Reprod Immunol 1997; 35:151.
82. Polzin WJ, Kopelman JN, Robinson RD, et al. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol 1991; 78:1108.
83. Harris EN, Spinnato, JA. Should anticardi-olipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol 1991; 165:1272.
84. Infante-Rivard C, David M, Gauthier, R, Rivard, GE. Lupus anticoagulants, anticardi-olipin antibodies, and fetal loss. N Engl J Med 1991; 325:1063.
85. Lockwood CJ, Romero R, Feinberg RF, et al. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989; 161:369.
86. Parke AL, Wilson D, Maier, D. The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant. Arthritis Rheum 1991; 34:1231.
87. Petri M, Golbus, M, Anderson, R, et al. Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopath-ic habitual abortion. A controlled, prospective study of forty-four women. Arthritis Rheum 1987; 30:601.
88. Haddow JE, Rote NS, Dostal-Johnson, D, et al. Lack of an association between late fetal death and antiphospholipid antibody measurements in the second trimester. Am J Obstet Gynecol 1991; 165:1308.
